Grand Pharmaceutical GroupCGPHF 87 Quick Ratio is 0.93 as of Dec. 2025, which is 3% above its 10-year median of 0.90. GuruFocus rates CGPHF with a GF Score™ of 87/100. The stock has 6 warning signs investors should review. Among 997 Drug Manufacturers companies, Grand Pharmaceutical Group ranks worse than 69.61% on this metric.
Grand Pharmaceutical Group has a quick ratio of 0.93. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for Grand Pharmaceutical Group's Quick Ratio or its related term are showing as below:
CGPHF'
s Quick Ratio Range Over the Past 10 Years
Min: 0.54 Med: 0.9 Max: 1.02
Current: 0.93
During the past 13 years, Grand Pharmaceutical Group's highest Quick Ratio was 1.02. The lowest was 0.54. And the median was 0.90.
CGPHF's Quick Ratio is ranked worse than 69.61% of 997
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs CGPHF: 0.93
Grand Pharmaceutical Group (OTCPK:CGPHF) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Grand Pharmaceutical Group Quick Ratio Related Terms
Grand Pharmaceutical Group Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Grand Pharmaceutical Group's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grand Pharmaceutical Group Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grand Pharmaceutical Group's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Grand Pharmaceutical Group's Quick Ratio falls into.
Grand Pharmaceutical Group Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grand Pharmaceutical Group (CGPHF) has a Quick Ratio of 0.93 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Grand Pharmaceutical Group and its competitors. This is near median its historical median of 0.90. Over the past decade, Grand Pharmaceutical Group's Quick Ratio has ranged from 0.54 to 1.02. According to the industry distribution chart, Grand Pharmaceutical Group ranks #694 out of 997 companies in the Drug Manufacturers industry, placing it in the top 69.6%.
Is Grand Pharmaceutical Group's Quick Ratio too high?
Grand Pharmaceutical Group's current Quick Ratio of 0.93 is near median its 10-year median of 0.90. Over the past 10 years, this metric has ranged from a low of 0.54 to a high of 1.02. The Drug Manufacturers industry median Quick Ratio is 1.45. Grand Pharmaceutical Group's value of 0.93 is 35.9% below this industry median. Based on the distribution chart, Grand Pharmaceutical Group ranks #694 out of 997 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Grand Pharmaceutical Group has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does Grand Pharmaceutical Group's Quick Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Grand Pharmaceutical Group ranks #694 out of 997 companies for Quick Ratio. This places Grand Pharmaceutical Group in the lower half of its industry. The industry median Quick Ratio is 1.45. Grand Pharmaceutical Group's value of 0.93 is 35.9% below this benchmark. Historically, Grand Pharmaceutical Group's own Quick Ratio has ranged from 0.54 to 1.02 over the past decade. While the company's 10-year median is 0.90 vs. the industry median of 1.45, Grand Pharmaceutical Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grand Pharmaceutical Group's current Quick Ratio of 0.93 is 35.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Grand Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grand Pharmaceutical Group's current Quick Ratio is 0.93, which is near median its own 10-year median of 0.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grand Pharmaceutical Group stock overvalued right now?
Grand Pharmaceutical Group (CGPHF) has a current Quick Ratio of 0.93. The current Quick Ratio is 0.93, which is near median its 10-year median of 0.90 and 35.9% below the Drug Manufacturers industry median of 1.45. Grand Pharmaceutical Group's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Grand Pharmaceutical Group (CGPHF), the current Quick Ratio is 0.93 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Grand Pharmaceutical Group Ltd are principally engaged in the manufacture and sales of pharmaceutical technology products, manufacture and sales of bio-technology products as well as manufacture and sales of nuclear medicine anti-tumor diagnosis and treatment and cerebro-cardiovascular precision interventional diagnosis and treatment technology products, in the People's Republic of China. The operation of the group constitutes one single reportable segment. The company has presence in The PRC, America, Europe, Asia other than the PRC and Others. The majority of revenue comes from the PRC. Its brands are breathe, biology, Cardiovascular emergency care, Cardiovascular intervention, ENT, tumor.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CGPHF has been successfully added to your 